Display options
Cite
Ponizovsky AM, Marom E, Ben-Laish M, et al. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Isr J Health Policy Res. 2016;5:16doi: 10.1186/s13584-016-0074-7.
Ponizovsky, A. M., Marom, E., Ben-Laish, M., Barash, I., Weizman, A., & Schwartzberg, E. (2016). Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Israel journal of health policy research, 516. https://doi.org/10.1186/s13584-016-0074-7
Ponizovsky, Alexander M, et al. "Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013." Israel journal of health policy research vol. 5 (2016): 16. doi: https://doi.org/10.1186/s13584-016-0074-7
Ponizovsky AM, Marom E, Ben-Laish M, Barash I, Weizman A, Schwartzberg E. Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013. Isr J Health Policy Res. 2016 Jun 15;5:16. doi: 10.1186/s13584-016-0074-7. eCollection 2016. PMID: 27307984; PMCID: PMC4908675.
Copy Download .nbib Format: NLM
Share it on

Isr J Health Policy Res. 2016 Jun 15;5:16. doi: 10.1186/s13584-016-0074-7. eCollection 2016.

Trends in the use of antipsychotics in the Israeli inpatient population, 2004-2013.

Israel journal of health policy research

Alexander M Ponizovsky, Eli Marom, Michal Ben-Laish, Igor Barash, Abraham Weizman, Eyal Schwartzberg

Affiliations

  1. Mental Health Services, Ministry of Health, Jerusalem, Israel ; 35/1 Ha-Kinor St., Ma'ale Adumim, 9837125 Israel.
  2. Pharmaceutical Administration, Ministry of Health, Jerusalem, Israel.
  3. Mental Health Services, Ministry of Health, Jerusalem, Israel.
  4. Research Unit, Geha Mental Health Center and Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

PMID: 27307984 PMCID: PMC4908675 DOI: 10.1186/s13584-016-0074-7

Abstract

BACKGROUND: Although serious mental illneses are treated with both typical and atypical antipsychotic grugs, trends in their use in psychiatric inpatient population in Israel are unrecognized. The aim of this study was to detect trends in the use of typical and atypical antipsychotic drugs in the Israeli inpatient psychiatric population throughout the last decade.

METHODS: Data regarding allocation of typical and atypical antipsychotics, over the period 2004 to 2013, were extracted from the electronic records of SAREL, Israel's largest private supplier of drugs to healthcare and medical facilities. The data were converted to defined daily doses (DDD) per 1000 inpatients per day.

RESULTS: Usage of the ten atypical antipsychotic agents allocated through Israel's national health care system increased by 73 %, from 128.09 DDD/1000 inpatients/day in 2004 to 221.69 DDD/1000 inpatients/day in 2013. This rise from 2004 to 2013 was largely due to a 1.6-fold increase in the administration of olanzapine (48.31 to 79.57 DDD/1000 inpatients/day), a 4.4-fold increase of quetiapine (9.74 to 43.04 DDD/1000 inpatients/day) and 3.7-fold increase of amisulpride (5.54 to 20.38 DDD/1000 inpatients/day). At the same period, the total utilization of 12 main typical antipsychotics decreased by 15.5 %, from 148.67 DDD/1000 inpatients/day in 2004 to 125.57 DDD/1000 inpatients/day in 2013. Over the entire period, total DDDs of both classes of antipsychotics (typical and atypical) increased by 38 %.

CONCLUSIONS: Similar to trends in the treatment of psychiatric outpatients in other countries, there was a substantial increase in the administration of atypical antipsychotic drugs to the Israeli psychiatric inpatient population across the study period. A decrease in the use of typical antipsychotics (substitution), polypharmacy, administration for more indications (supplementation) and the use of larger doses of antipsychotics may account, in part, for this increase. The findings have implications for mental health policy in the context of the Mental Health Care System Reform. Systematic studies on appropriate dosing of antipsychotics and augmentation strategies are warranted.

Keywords: Amisulpride; Aripiprazole; Atypical antipsychotics; Clozapine; Iloperidone; Olanzapine; Paliperidone; Pharmacoepidemiology; Quetiapine; Risperidone; Sertindole; Typical antipsychotics; Ziprasidone

References

  1. Clinicoecon Outcomes Res. 2012;4:13-9 - PubMed
  2. Mol Psychiatry. 2009 Apr;14(4):429-47 - PubMed
  3. Annu Rev Med. 2013;64:393-406 - PubMed
  4. J Nerv Ment Dis. 2012 Jul;200(7):637-43 - PubMed
  5. Aust N Z J Psychiatry. 2010 Apr;44(4):372-7 - PubMed
  6. CNS Drugs. 2013 Jul;27(7):515-29 - PubMed
  7. Isr J Psychiatry Relat Sci. 2010;47(3):171-83; discussion 183-94 - PubMed
  8. Arch Gen Psychiatry. 1997 Jun;54(6):549-57 - PubMed
  9. Arch Gen Psychiatry. 2002 May;59(5):441-8 - PubMed
  10. Ann Intern Med. 2012 Oct 2;157(7):498-511 - PubMed
  11. Australas Psychiatry. 2006 Jun;14(2):169-74 - PubMed
  12. Aust N Z J Psychiatry. 2012 Aug;46(8):762-73 - PubMed
  13. Appl Health Econ Health Policy. 2013 Apr;11(2):95-106 - PubMed
  14. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006369 - PubMed
  15. Hum Psychopharmacol. 2010 Mar;25(2):179-86 - PubMed
  16. Acta Psychiatr Scand. 2010 Jan;121(1):4-10 - PubMed
  17. Aust N Z J Psychiatry. 2013 Jan;47(1):74-87 - PubMed
  18. Hum Psychopharmacol. 2005 Jul;20(5):355-8 - PubMed
  19. Arch Pediatr Adolesc Med. 2004 Aug;158(8):753-9 - PubMed
  20. Eur Psychiatry. 2011 May;26(4):265-9 - PubMed
  21. Am J Psychiatry. 2002 Feb;159(2):255-62 - PubMed
  22. Pharmacotherapy. 2013 Mar;33(3):344-59 - PubMed
  23. Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):177-84 - PubMed
  24. Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):835-8 - PubMed
  25. Harv Rev Psychiatry. 2002 Sep-Oct;10(5):280-91 - PubMed
  26. Health Aff (Millwood). 2009 Sep-Oct;28(5):w770-81 - PubMed
  27. Lancet. 2013 Sep 14;382(9896):951-62 - PubMed
  28. Am J Health Syst Pharm. 2014 May 1;71(9):728-38 - PubMed
  29. J Psychopharmacol. 2009 Jun;23(4):346-88 - PubMed
  30. Ann Med Health Sci Res. 2013 Jan;3(1):62-6 - PubMed
  31. Br J Psychiatry. 1995 Jun;166(6):712-26; discussion 727-33 - PubMed

Publication Types